Aptah Bio’s Post

ExoProTher eagerly awaits the State-of-the-Art Envision NTA Machine from HYPERION ANALYTICAL We are excited to share that the brand-new, and Israel's first, Nanoparticle Tracking Analysis (NTA) machine of this kind – Envision from Hyperion Analytical LLC, is on the way to ExoProTher’s labs. The Envision will significantly enhance our analytical capabilities and data reliability. Our investment in the HYPERION NTA Envision underscores our commitment to pioneering science and best quality data behind the development of p53 replacement therapy for oncology indications.   Watch this space for more updates!   #nanoparticletrackinganalysis #innovation #p53replacementtherapy #biotechnology #oncology

Illumina Connected Insights 3.0 is here! Visualize, interpret and create reports for #DRAGEN's somatic workflows, TSO-500 solid and liquid assays with the just released ICI 3.0. https://lnkd.in/gJgWeHSE #Oncology #NGS #Bioinformatics #Interpretation

Faron has today published its full-year financial #results for the twelve months ended 31 December 2023.    You can read the full statement here: https://lnkd.in/d3hnaSma   #Faron #biotech #drugdevelopment #oncology

"We’ve seen a shift in the past few years from there being really good companies in China focused on healthcare delivery, manufacturing, and CRO services to the point where there is now true pharma and biotech innovation happening. This transformation has been impressive. " Founded in 2014 and based in China and the US, Zai Lab is actively partnering with companies globally to in-license and/or co-develop best-in-class and first-in-class therapies in important disease areas. Read to know more about their strategy and approach. #QMportfolio #QMhealthcare #insights #chinabiotech #chinainnovation #chinahealthcare

ICYMI – Last week, BioCentury Inc. covered Amphista’s unveiling of a new mechanism of action (MOA) for the degradation of BRD9, an emerging target in #oncology, on Wednesday 22 May by our Senior Director, Discovery Chemistry, Dr Andrea Testa. The demonstration of BRD9 degradation in vivo via this MOA, which is completely differentiated from cereblon- or VHL-based PROTACs, marks a significant step forward in the #TPD field. It underscores Amphista’s proprietary chemistry and high-quality science, which we are applying to the discovery and development of additional targeted glues to expand the offering of TPD medicines beyond CRBN and VHL-based agents and bring effective treatments to patients in areas of high unmet need. Read the full piece by Danielle Golovin, Ph.D. here: https://lnkd.in/eftFtfHf #BioCentury #DrugDiscovery #Biotech #TargetedProteinDegradation #CeTPD

In a recent article by Drug Discovery & Development, Zai Lab’s President and COO Josh Smiley discusses the impact of Asia-based companies such as Zai Lab on global #drugdiscovery and development. Read more: https://bit.ly/4aJ3VK9 #drugdevelopment #oncology #biotech #autoimmunedisorders #infectiousdiseases #neurologicaldisorders

We will be hosting a virtual BEXMAB update event on Tuesday, March 19 at 9am GMT/11.00 EET. During the event we will discuss the latest data from our ongoing BEXMAB study, investigating the safety and efficacy of #bexmarilimab, our wholly owned #immunotherapy candidate, in combination with standard of care in patients with hypomethylating agents (HMAs)-refractory or relapsed #acuteMyeloidLeukemia and #MyelodysplasticSyndromes. Participants of the webcast will include Dr. Mika Kontro, MD, PhD, Associate Professor at the University of Helsinki and BEXMAB Principal Investigator, Dr. Maija Hollmén, PhD, Chief Scientific Officer at Faron, Dr. Juho Jalkanen MD, PhD, Chief Operating Officer at Faron and members of Faron’s senior management team. To register visit: https://lnkd.in/d9iHDmKr #Faron #biotech #drugdevelopment #oncology

Save the date! October 15-18, 2024 4th edition of #BioMaH Conference will be held in Rome organized by the CNR - ISM Istituto di Struttura della Materia of Consiglio Nazionale delle Ricerche. #bioengineering #biofabrication #biomedical #biotechnology #cancer #cell #biomah #materialsscience #mdpi #eors More information can be found at https://biomah.ism.cnr.it

In our on-demand Tech Talk, Katharina Krohn, Vice President Global Biobanks, reveals the keys to revolutionizing personal medicine through the use of biobanks. In this webinar, you will discover what you should consider when selecting a type of biobank and how to identify crucial sample data sets. Learn more about: ✅Proper quality control ensures that biospecimens are suitable for their intended use ✅Variables in the pre-analytical phase (collection, processing, and storage) significantly impact sample quality Watch the full on-demand webinar – which is less than 20 minutes - at your convenience. ➡️ https://bit.ly/4996anT #Biospecimen #Biobank #Oncology

Liquid Biopsy Market worth $11.3 billion by 2029 Download PDF Brochure:-https://lnkd.in/dXCAX_mY The size of global liquid biopsy market in terms of revenue was estimated to be worth $6.4 billion in 2024 and is poised to reach $11.3 billion by 2029, growing at a CAGR of 11.9% from 2024 to 2029. 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞 Natera. QIAGEN Myriad Genetics, Illumina Wohlfahrtsstiftung der F. Hoffmann-La Roche AG Thermo Fisher Scientific Bio-Rad Laboratories, Exact Sciences Sysmex Corporation Biocept, Inc. , mdxhealth Personalis, Inc. NeoGenomics Laboratories Epigenomics AG Menarini Silicon Biosystems Vortex Biosciences Bio-Techne MEDGENOME Mesa labs. Laboratory Corporation of America Holdings Freenome Holdings Inc, Strand Life Sciences LungLife AI Lucence #liquidbiopsy #cancerdiagnostics #precisionmedicine #oncology #moleculardiagnostics